Jiangsu Yingke Biopharmaceutical

Jiangsu Yingke Biopharmaceutical Co., Ltd. is a biopharmaceutical company established on January 25, 2011, that integrates research and development, manufacturing, and sales. The company is located in the Taizhou National Medical Hi-tech Development Zone, also known as China Medical City.

The firm specializes in the R&D of products in fields including parenteral nutrition, anesthesia, and oncology. It focuses on creating fat emulsion series products, such as its Propofol Medium and Long Chain Fat Emulsion Injection, which was the first of its kind to be approved in China and was selected for the national centralized drug procurement program. Its product lineup also includes both launched and pre-launch drugs like Propofol Injectable Emulsion and various anesthetic creams. The company's business model combines in-house R&D with manufacturing and sales, aiming to become a key player in the fat emulsion segmentation market. Many of its products are listed in the National Essential Drug Catalog.

Jiangsu Yingke Biopharmaceutical operates multiple workshops compliant with new Good Manufacturing Practice (GMP) standards, including facilities for bulk drugs, freeze-dried powder injections, and both small and large-volume injections. Since its inception, the company has achieved significant milestones, passing its first GMP certification in 2013 and being recognized as a "National high-tech Enterprise" in 2015. In June 2023, the company secured $42.2 million in a Series B funding round.

Keywords: biopharmaceutical, generic drugs, fat emulsion, injectable drugs, parenteral nutrition, anesthesia, oncology pharmaceuticals, GMP manufacturing, pharmaceutical R&D, Propofol, drug development, China Medical City, pharmaceutical manufacturing, healthcare, life sciences, injectable emulsion